查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611851

蛋白酪氨酸激酶抑制劑市場：按類型、應用和最終用戶分類 - 2025-2030 年全球預測

Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

蛋白酪氨酸激酶抑制劑市場2023年估值為590.7億美元，預計到2024年將達到634.6億美元，複合年成長率為7.17%，預計到2030年將達到959.5億美元。

蛋白酪氨酸激酶抑制劑 (TKI) 是一組抑制蛋白酪氨酸激酶的標靶癌症治療方法，酪胺酸激酶是一種對訊號傳導和細胞分裂控制等細胞功能很重要的酵素。 TKI 在治療各種惡性，包括白血病、肺癌和乳癌，而傳統治療方法往往不足以滿足這些癌症的需求。對 TKI 的需求在於它們能夠針對特定訊號通路，提供可降低全身毒性並提高患者特異性效率的治療選擇。它的應用範圍超出了腫瘤學，包括類類風濕性關節炎和慢性發炎等疾病。最終使用範圍主要是醫院、專門的癌症治療中心和專注於個人化醫療的研究機構。

主要市場統計
基準年[2023] 590.7億美元
預計年份 [2024] 634.6億美元
預測年份 [2030] 959.5億美元
複合年成長率（%） 7.17%

市場成長受到全球癌症發生率上升、基因組科學進步以及精準醫療需求增加等因素的顯著影響。最近的趨勢包括開發具有更高特異性的下一代 TKI，並擴大其在基因治療和罕見疾病領域的應用。為了利用這些機會，公司應該投資研發合作並鼓勵適應性臨床試驗以加速藥物核准。然而，新興市場面臨開發成本高、抗藥性突變、重大監管障礙以及安全性和有效性問題等挑戰。

創新的治療領域包括研究將 TKI 和免疫聯合治療結合起來以提高治療效果，以及利用人工智慧來識別新標靶並最佳化藥物設計，鑑於其獨特的性質，這是一個有前途的途徑。市場競爭激烈但分散，大型製藥企業和快速成長的生物技術公司佔據市場主導地位，導致不斷創新，但小型企業要成功也需要戰略聯盟。總之，為了永續成長，該產業應專注於克服抗藥性機制、擴大治療適應症以及提高全球治療藥物的價格和可用性。

市場動態：快速發展的蛋白酪氨酸激酶抑制劑市場的關鍵市場洞察

蛋白酪氨酸激酶抑制劑市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症流行和標靶治療的增加
    • 改善天然蛋白酪氨酸激酶抑制劑在醫藥配方中的使用
  • 市場限制因素
    • 與抗藥性發展和藥物交互作用相關的限制
  • 市場機會
    • 持續研究活動以提高蛋白酪氨酸激酶抑制劑的質量
    • 政府對蛋白酪氨酸激酶抑制劑的有利核准
  • 市場挑戰
    • 對蛋白酪氨酸激酶抑制劑肝毒性的擔憂

波特五力：開拓蛋白酪氨酸激酶抑制劑市場的策略工具

波特的五力框架是了解蛋白酪氨酸激酶抑制劑市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解蛋白酪氨酸激酶抑制劑市場的外部影響

外部宏觀環境因素在塑造蛋白酪氨酸激酶抑制劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解蛋白酪氨酸激酶抑制劑市場的競爭格局

對蛋白酪氨酸激酶抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣蛋白酪氨酸激酶抑制劑市場供應商績效評估

FPNV 定位矩陣是評估蛋白酪氨酸激酶抑制劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了蛋白酪氨酸激酶抑制劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對蛋白酪氨酸激酶抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症流行和標靶治療的增加
      • 改善天然蛋白酪氨酸激酶抑制劑在藥物製劑中的使用
    • 抑制因素
      • 與抗藥性發展和配方相互作用相關的限制
    • 機會
      • 持續進行研究活動以提高蛋白酪氨酸激酶抑制劑的質量
      • 政府對蛋白酪氨酸激酶抑制劑的有利核准
    • 任務
      • 對蛋白酪氨酸激酶抑制劑肝毒性的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章蛋白酪氨酸激酶抑制劑市場：依類型

  • BCR-ABL
  • 表皮生長因子受體
  • 血管內皮生長因子受體

第7章蛋白酪氨酸激酶抑制劑市場：依應用分類

  • 乳癌
  • 慢性骨髓性白血病
  • 肺癌
  • 腎臟細胞癌

第8章蛋白酪氨酸激酶抑制劑市場：按最終用戶

  • 居家護理
  • 醫院
  • 專科診所

第9章美洲蛋白酪氨酸激酶抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區蛋白酪氨酸激酶抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲蛋白酪氨酸激酶抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline PLC
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals , Inc.
  • Steris Healthcare Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B168537796FC

The Tyrosine Kinase Inhibitors Market was valued at USD 59.07 billion in 2023, expected to reach USD 63.46 billion in 2024, and is projected to grow at a CAGR of 7.17%, to USD 95.95 billion by 2030.

Tyrosine Kinase Inhibitors (TKIs) are a class of targeted cancer therapies that impede tyrosine kinases-enzymes crucial for cellular functions such as signal transduction and regulation of cell division. The scope of TKIs spans their pivotal role in treating various malignancies, including leukemia, lung cancer, and breast cancer, where traditional therapies often fall short. The necessity of TKIs lies in their ability to target specific signaling pathways, offering a treatment alternative that can reduce systemic toxicity and increase patient-specific efficiency. Their applications extend beyond oncology, including conditions like rheumatoid arthritis and chronic inflammation. The end-use scope is predominantly within hospitals, specialized cancer treatment centers, and research institutions focusing on personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 59.07 billion
Estimated Year [2024] USD 63.46 billion
Forecast Year [2030] USD 95.95 billion
CAGR (%) 7.17%

Market growth is influenced heavily by factors such as rising global cancer incidence, advancements in genomics, and increased demand for precision medicine. Recent opportunities include the development of next-generation TKIs with improved specificity and the expansion of their application in gene therapy and rare diseases. To leverage these opportunities, companies should invest in R&D collaborations and encourage adaptive clinical trials to fast-track drug approvals. However, the market faces challenges like high development costs, resistance mutations, and significant regulatory hurdles tied to safety and efficacy concerns.

Innovative areas include exploring combination therapies that pair TKIs with immunotherapies to enhance treatment efficacy, and leveraging artificial intelligence to identify new targets and optimize drug design-a promising avenue given the complex nature of kinase pathways. The market is competitive yet fragmented, dominated by both established pharma giants and burgeoning biotech firms, leading to constant innovation but also necessitating strategic partnerships for smaller players to succeed. In conclusion, for sustained growth, the industry should focus on overcoming resistance mechanisms, expanding therapeutic indications, and addressing the affordability and accessibility of these treatments globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tyrosine Kinase Inhibitors Market

The Tyrosine Kinase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancer and increasing adoption of targeted therapy
    • Improved use of natural tyrosine kinase inhibitors in medical formulations
  • Market Restraints
    • Limitations associated with resistance development and formulation interactions
  • Market Opportunities
    • Ongoing research activities to improve the quality of tyrosine kinase inhibitors
    • Favorable government approvals for Tyrosine Kinase Inhibitors
  • Market Challenges
    • Concerns associated with hepatotoxicity of tyrosine kinase inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Tyrosine Kinase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tyrosine Kinase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tyrosine Kinase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tyrosine Kinase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tyrosine Kinase Inhibitors Market

A detailed market share analysis in the Tyrosine Kinase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tyrosine Kinase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tyrosine Kinase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tyrosine Kinase Inhibitors Market

A strategic analysis of the Tyrosine Kinase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tyrosine Kinase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Cipla Limited, Eisai Co. Ltd., Eli Lilly and Company , F. Hoffmann-La Roche, GlaxoSmithKline PLC, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Johnson & Johnson Services, Inc., Lupin Limited, Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals , Inc., Steris Healthcare Pvt. Ltd., and Takeda Pharmaceutical Company Limited .

Market Segmentation & Coverage

This research report categorizes the Tyrosine Kinase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across BCR-ABL, Epidermal Growth Factor Receptor, and Vascular Endothelial Growth Factor Receptor.
  • Based on Application, market is studied across Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer, and Renal Cell Cancer.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer and increasing adoption of targeted therapy
      • 5.1.1.2. Improved use of natural tyrosine kinase inhibitors in medical formulations
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations associated with resistance development and formulation interactions
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to improve the quality of tyrosine kinase inhibitors
      • 5.1.3.2. Favorable government approvals for Tyrosine Kinase Inhibitors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with hepatotoxicity of tyrosine kinase inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tyrosine Kinase Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. BCR-ABL
  • 6.3. Epidermal Growth Factor Receptor
  • 6.4. Vascular Endothelial Growth Factor Receptor

7. Tyrosine Kinase Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Chronic Myeloid Leukemia
  • 7.4. Lung Cancer
  • 7.5. Renal Cell Cancer

8. Tyrosine Kinase Inhibitors Market, by End-Users

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Tyrosine Kinase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tyrosine Kinase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tyrosine Kinase Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. Boehringer Ingelheim International
  • 4. Bristol-Myers Squibb Company
  • 5. Cipla Limited
  • 6. Eisai Co. Ltd.
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche
  • 9. GlaxoSmithKline PLC
  • 10. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Lupin Limited
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Spectrum Pharmaceuticals , Inc.
  • 16. Steris Healthcare Pvt. Ltd.
  • 17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. TYROSINE KINASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. TYROSINE KINASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TYROSINE KINASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023